Age-related effects of antihypertensive therapy with α-blockers

Journal of Cardiovascular Pharmacology

Volumn 12, Issue 8, 1988, Pages S109-S115

  Stokes, G S ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Age; Hypertension; Adrenoceptor antagonists

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; INDORAMIN; KETANSERIN; LABETALOL; NORADRENALIN; PHENYLEPHRINE; PRAZOSIN; TERAZOSIN; TRIMAZOSIN;

AGE; AGED; HUMAN; HYPERTENSION; ORTHOSTATIC HYPOTENSION; PHARMACOKINETICS; PRIORITY JOURNAL; SHORT SURVEY;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; AGING; HUMAN; HYPERTENSION;

EID: 0024269908     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-198806128-00024     Document Type: Article

References (56)

1. Alps BJ. Johnson ES. Wilson AB. Cardiovascular actions of WY21901; a new hypotensive and antiarrhythmic agent. Br J Pharmacol 1970;40:151-2.
2. Stokes GS. Frost GW, Graham RM. MacCarthy EP. Indoramin and prazosin as adjuncts to β-adrenoceptor blockade in hypertension. Clin Pharmacol Thcr 1979:25:783-9.
3. Farmer JB. Kennedy I, Levy GP. Marshall RJ. Pharmacology of AH 5158; a drug which blocks both α- and β-adren-oceptors. Br J Pharmacol 1972:45:660-75.
4. Reimann IW. Frölich JC. Mechanism of antihypertensive action of ketanserin in man. Br Med J 1983:287:381-3.
5. Fagard R, Fiocchi R. Lignen P. el al. Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J 1984:51:149-56.
6. Davey MJ. Massingham R. A review of the biological effects of prazosin, including recent pharmacological findings. Curr Med Res Opin 1976/I977:4(suppl. 2):47-60.
7. Graham RM, Stephenson WH. Pettinger WA. Pharmacological evidence for a functional role of the prejunctional αadrenoceptor in noraderenergic neurotransmission in the conscious rat. Naunyn Schmied Arch Pharmacol 1980:311:129-38.
8. Awan NA. Miller RR. Maxwell K. Mason DT. Effects of prazosin on forearm resistance and capacitance vessels. Clin Pharmacol Ther 1977:22:79-84.
9. Fuller RW. Snoddy HD. Perry KW. Effect of prazosin on norepinephrine concentration and turnover in rat brain and heart. Arch Int Pharmacodyn 1978:231:30-6.
10. Leren P, Foss PO. Helgeland A. et al. Effect of propranolol and prazosin on blood lipids. The Oslo Study. Lancet 1980:2:4-6.
11. Lehtonen A. Himanen P, Saraste M, et al. Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins. Br J Clin Pharmacol 1986;21:77S-81S.
12. Anderson SD. Bye PTP. Perry CP. et al. Limitation of work performance in normal adult males in the presence of β-ad-renergic blockade. Attst NZ J Med 1979:9:515-20.
13. Torvik D, Madsbu H-P. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension. Am J Cardiol 1987;59:68-72G.
14. Mulvihill-Wilson J, Gaffney FA. Pettinger WA. et al. Hemodynamic and neuroendocrine response to acute and J Cardiovasc Pharmacol. Vol. 12 Sappl. St. 1988 chronic αadrenergic blockade with prazosin and phenoxy-benazmine. Circulation 1983:67:383-93.
15. Marlin GE. Thompson PJ. Reddel HK. Chow CM. Cheng S. Bronchodilator activity of prazosin in patients with allergic rhinitis and asthma. Br J Clin Pharmacol 1982:13:445-8.
16. Shiononi H. Noda K. Miyamoto K. et al. Glucose tolerance during chronic prazosin therapy in patients with essential hypertension. Curr Ther Res 1986:40:171-80.
17. Bauer. JH. Jones LB. Gaddy P. Effects of prazosin therapy on BP. renal function and bodv fluid composition. Arch Intern Med 1984:144:1196-200.
18. Packer M. Medina N. Yuchak M. Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe heart failure. J Am Coll Cardiol 1986:7:671-80.
19. Stokes GS. Marwood JF. Review of the use of u-adreno-ceptor antagonists in hypertension. Meth Find Exp Clin Pharmacol 1984:6:197-204.
20. Committee of Safety of Medicines. Adverse reactions series. no 12. London: DHSS. 1975.
21. Rubin PC. Scott PJW. Reid JL. Prazosin disposition in young and elderly subjects. Br J Clin Pharmacol 1981:12:401-4.
22. Elliott HL. Meredith PA. Vincent J. Reid JL. Clinical pharmacological studies with doxazosin. Br J Clin Pharmacol 1986;21:27S-31S.
23. Jaillon P. Clinical pharmacokinetics of prazosin. Clin Phar-macokin 1980;5:365-76.
24. Bateman DN. Hobbs DC. Twomey TM. et al. Prazosin, pharmacokinetics and concentration effect. Eur J Clin Pharmacol 1979:16:177-81.
25. Carlson RV, Bailey RR, Begg E. et al. Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. Clin Pharmacol Ther 1986:40:561-6.
26. Cubeddu LX. Fuenmayor N. Caplan N. Ferry D. Clinical pharmacology of doxazosin in patients with essential hypertension. Clin Pharmacol Ther 1987:41:439-49.
27. Taylor JA, Twomey TM, Schach von Wittenau M. The metabolic fate of prazosin. Xenobiotica 1977;7:357-64.
28. Bender AD. Pharmacologic aspects of ageing: a survey of the effects of increasing age on drug activity in adults. J Am Gerial Soc 1964:12:114-34.
29. Norbury HM. Franklin RA. Marrott PK. Warrington SJ. Pharmacokinetics of oral indoramin in elderly and middle-aged female volunteers. Eur J Clin Pharmacol 1984:27:2479.
30. Kelly JG. McGarry K. O' Malley K. O'Brien ET. Bioavailability of labetalol increases with age. Br J Clin Pharmacol 1982:14:304-5.
31. Tuttle RS. Age-related changes in the sensitivity of rat aortic strips to norepinephrine and associated chemical and structural alterations. J Gerontol 1966:21:510-16.
32. McAdams RP, Waterfall JF. The effect of age on the sensitivity of pre- and postsynaptic αadrenoceptors to agonists and antagonists in the rat. Naunyn Schmied Arch Pharmacol 1986:334:430-5.
33. Partilla JS, Hoopes MT. Ito H. Dux EM. Roth GS. Loss of rat ventricular α-adrenergic receptors during aging. Life Sci 1982:31:2507-12.
34. 2-adrenergic receptor number in human platelets. Eur J Pharmacol 1982:81:345-7.
35. Hyland L. Docherty JR. An investigation of age-related changes in pre- and postjunctional αadrenoceptors in human saphenous vein. Eur J Pharmacol 1985:114:361-4.
36. Scott PJW. Reid JL. The effect of age on the responses of human isolated arteries to noradrenaline. Br J Clin Pharmacol 1982:13:237-9.
37. Stevens MJ. Lipe S. Moulds RFW. The effect of age on the responses of human isolated arteries and veins to noradrenaline. Br J Clin Pharmacol 1982:14:750-2.
38. Elliott HL. Sumner DJ, McLean K, Rubin PC. Reid JL. Effeet of age on vascular αadrenoceptor responsiveness in man. Clin Sci 1982;63:305s-308s.
39. Bühler FR, Kiowski W, Van Brummelen P, et al. Plasma catecholamines and cardiac, renal and peripheral vascular adrenoceptor-mediated responses in different age groups of normal and hypertensive subjects. Clin Exp Hypertension 1980;2:409-26.
40. Van Brummelen P, Bühler FR, Kiowski W, Amann FW. Age-related decrease in cardiac and peripheral vascular responsiveness to isoprenaline: studies in normal subjects. Clin Sci 1981;60:571-7.
41. Aman FW, Bolli P, Kiowski W, Bühler FR. Enhanced αadrenoceptor mediated vasoconstriction in essential hypertension. Hypertension 1981;3:1119-1123.
42. Kiowski W, Bühler FR, Van Brummelen P, Amann FW. Plasma noradrenaline concentration and αadrenoceptor-me-diated vasoconstriction in normotensive and hypertensive man. Clin Sci 1981:60:483-9.
43. Bühler FR, Bolli P. Changes in cardiovascular responsiveness caused by age and high blood pressure: implications for therapy. J Cardiovasc Pharmacol 1985;7(suppl 3):S206-15.
44. Kelly J, O'Malley K. Adrenoceptor function and ageing. Clin Sci 1984;66:509-15.
45. Sever PS, Birch M, Osikowska B, Tunbridge RDG. Plasmαnoradrenaline in essential hypertension. Lancet 1977;1:1078-81.
46. Weidmahn P, De Mytteaere-Bursztein S, Maxwell MH, Liwa JD. Effect of ageing on plasma renin and aldosterone in normal man. Kidney Int 1975;8:325-33.
47. 2-adrenergic receptors in male rats. J Biol Chem 1983;258:5103-09.
48. Lynch CJ, Charest R, Blackmore PF, Exton JH. Studies on the hepatic α-adrenergic receptor. Modulation of guanine nucleotide effects by calcium, temperature and age. J Biol Chem 1985:260:1593-1600.
49. Ram CVS, Meese R, Kaplan NM, et al. Antihypertensive therapy in the elderly. Am J Med 1987;82(suppl 1A):53-7.
50. Caird FI, Andrews GR, Kennedy RD. Effect of posture on blood pressure in the elderly. Brit Heart J 1973;35:527-30.
51. Gribbin B, Pickering TG, Sleight P, Peto R. Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res 1971;29:424-31.
52. Rubin PC, Blaschke TF. Studies on the clinical pharmacology of prazosin. 1: Cardiovascular, catecholamine and endocrine changes following a single dose. Br J Clin Pharmacol 1980;10:23-32.
53. Elliott HL, McLean K, Summer DJ, Meredith PA, Reid JL. Immediate cardiovascular responses to oral prazosin. Effects of concurrent β-blockers. Clin Pharmacol Ther 1981 ;29:303-9.
54. Seidemann P, Grahnen A, Haglund K, Lindstrom B, Von Bahr C. Prazosin first dose phenomenon during combined treatment with a β-adrenoceptor blocker in hypertensive patients. Br J Clin Pharmacol 1982;13:865-70.
55. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985:312:227-83.
56. Seth L, Galie N, Casebolt . et al. Indoramin in heart failure: possible adverse effects on hemodynamics and exercise capacity. Clin Pharmacol Ther 1986;40:567-74.